Seroquel XR approved for maintenance treatment
Executive Summary
AstraZeneca's once-daily Seroquel XR (quetiapine fumarate) is approved Nov. 15 for maintenance treatment of schizophrenia in adult patients. The once-daily atypical antipsychotic agent was first approved in May 2007 for acute treatment of schizophrenia. AstraZeneca hopes to get approval for treatment of bipolar disorder, major depressive disorder and generalized anxiety disorder by next October. AstraZeneca plans to use Seroquel XR to drive the growth of the total franchise, and not simply switch patients from the immediate-release product to the sustained-release regimen (1"The Pink Sheet" Nov. 5, 2007, p. 3)...